Immunotherapeutic Use Expanded to Head and Neck Cancer
The U.S. FDA decision to approve nivolumab for head and neck cancer means nivolumab is now an approved treatment for five types of cancer.
The U.S. FDA decision to approve nivolumab for head and neck cancer means nivolumab is now an approved treatment for five types of cancer.
A recent study reports that how pediatricians talk to parents can affect whether or not they chose to have their child vaccinated against human papillomavirus (HPV). For pediatricians and parents of adolescents, across the...
Each of the three obesity-related factors, body mass index (BMI), waist size, and type 2 diabetes, was associated with liver cancer risk in a large study.
An investigational immunotherapeutic was safe, tolerable, and showed some activity against melanoma in a phase I clinical trial.
The FDA approved a molecularly targeted therapeutic for treating certain patients with soft tissue sarcoma.
The number of Hispanic breast cancer patients in California getting care and participating in a clinical trial increased, a study found.
The lack of androgen receptor protein may contribute to racial disparities in survival for women with this aggressive form of breast cancer.
The FDA expanded the use of an immunotherapy to include the treatment of certain patients with lung cancer.
In an early-phase trial, investigators study whether combining immunotherapies expands “tumor-specific immune activation.” A small phase Ib study of a combination of an investigational cytokine-based immunotherapy and the checkpoint inhibitor pembrolizumab (Keytruda) showed promise...
Researchers seek to understand why some patients do not respond to immunotherapeutics while others achieve durable outcomes.